Press release
Amyotrophic Lateral Sclerosis Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Explore our latest breakthroughs in Amyotrophic Lateral Sclerosis research. Learn more about our innovative pipeline today! @ Amyotrophic Lateral Sclerosis Pipeline Outlook- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
• June 2024:- Argenx- A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis.
• June 2024:- Axoltis Pharma- A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c.
• June 2024:- Biogen- A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation. The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF).
• DelveInsight's Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
• The leading Amyotrophic Lateral Sclerosis Companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
• Promising Amyotrophic Lateral Sclerosis Therapies such as Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), ION363, and others.
Stay informed about the cutting-edge advancements in Amyotrophic Lateral Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Amyotrophic Lateral Sclerosis Emerging Drugs Profile
• MN-166: MediciNova
MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of ALS.
• RNS60: Revalesio
RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. The drug activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the US Food and Drug Administration. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.
• VM202: Helixmith
VM202 is an innovative gene therapy drug that provides fundamental treatment through tissue regeneration. The drug is injected along the peripheral nerves and their branches, the internal production of HGF may protect nerves and promote the growth of neurons while also ameliorating atrophic conditions. The US FDA granted orphan drug and fast track designation to VM202. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.
• QRL-201: QurAlis Corporation
QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. The drug is currently being evaluated under Phase I clinical trial for the Amyotrophic Lateral Sclerosis treatment.
Learn more about Amyotrophic Lateral Sclerosis Drugs opportunities in our groundbreaking Amyotrophic Lateral Sclerosis Research and development projects @ Amyotrophic Lateral Sclerosis Unmet Needs- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide
Discover the latest advancements in Amyotrophic Lateral Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Amyotrophic Lateral Sclerosis Pipeline Report
• Coverage- Global
• Amyotrophic Lateral Sclerosis Companies- Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
• Amyotrophic Lateral Sclerosis Therapies- Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), ION363, and others.
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Amyotrophic Lateral Sclerosis Pipeline on our website @ Amyotrophic Lateral Sclerosis Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. MN-166: MediciNova
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. QRL-201: QurAlis Corporation
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Amyotrophic Lateral Sclerosis Key Companies
21. Amyotrophic Lateral Sclerosis Key Products
22. Amyotrophic Lateral Sclerosis- Unmet Needs
23. Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
24. Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
25. Amyotrophic Lateral Sclerosis Analyst Views
26. Amyotrophic Lateral Sclerosis Key Companies
27. Appendix
List of Top Selling Market Research Reports in 2024
Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market
About DelveInsight
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyotrophic Lateral Sclerosis Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024 here
News-ID: 3654335 • Views: …
More Releases from DelveInsight Business Research LLP

Pharmaceutical Contract Manufacturing Market Forecast Report 2032: Size, Share, …
DelveInsight's Pharmaceutical Contract Manufacturing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Pharmaceutical Contract Manufacturing Companies market shares, challenges, Pharmaceutical Contract Manufacturing Market Drivers, barriers, trends, and key market Pharmaceutical Contract Manufacturing companies in the market.
To read more about the latest highlights related to the Pharmaceutical Contract Manufacturing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/pharmaceutical-contract-manufacturing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key…

Pharmaceuticals Market Forecast Report 2032: Size, Share, and Strategic Insights …
DelveInsight's Pharmaceuticals Market Insights Report 2032 provides the current and forecast market analysis, individual leading Pharmaceuticals Companies market shares, challenges, Pharmaceuticals Market Drivers, barriers, trends, and key market Pharmaceuticals companies in the market.
To read more about the latest highlights related to the Pharmaceuticals Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/pharmaceutical-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Pharmaceuticals Market Report
• In July 2025, Sanofi announced the…

Checkpoint Inhibitors Competitive Landscape Report 2025: Emerging Therapies, Lea …
DelveInsight's, "Checkpoint Inhibitors Competitive landscape 2025" report provides comprehensive insights about 50+ companies and 60+ drugs in Checkpoint Inhibitors Competitive landscape. It covers the Checkpoint Inhibitors Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving Checkpoint Inhibitors Pipeline and discover which companies are leading the innovation race @ Checkpoint Inhibitors Competitive…

Surgical Simulation Market Forecast Report 2032: Size, Share, and Strategic Insi …
DelveInsight's Surgical Simulation Market Insights Report 2032 provides the current and forecast market analysis, individual leading Surgical Simulation Companies market shares, challenges, Surgical Simulation Market Drivers, barriers, trends, and key market Surgical Simulation companies in the market.
To read more about the latest highlights related to the Surgical Simulation Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/surgical-simulation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Surgical Simulation Market…
More Releases for Late
Transformative Trends Impacting the Late Stage Chronic Kidney Disease Drugs Mark …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Late Stage Chronic Kidney Disease Drugs Market Size By 2025?
In recent times, the market size for drugs treating late-stage chronic kidney disease has experienced a swift growth. It is projected to rise from $7.08 billion in 2024 to $7.86 billion in 2025, indicating a…
Late Night Revelry Awaits at The Winslow Lounge - NYC's Premier Late-Night Desti …
Image: https://www.getnews.info/wp-content/uploads/2024/06/1713864312.jpeg
New York, NY - The Winslow Lounge, located in the heart of the East Village, has quickly become the premier late-night destination [https://thewinslownyc.com/late-night-bar-nyc/] in New York City. With its vibrant atmosphere, exciting entertainment options, delicious food and drinks, and lively events, The Winslow offers an unforgettable nightlife experience.
"We wanted to create a place in NYC where people could truly let loose and have an amazing time," said Mark Tafoya,…
Desperate Puppy Seeks Rescue Before It’s Too Late!
FOR IMMEDIATE RELEASE
Tucson AZ, December 14th, 2021
The StarBarksCoffee.com rescue team was recently assaulted and threatened with being shot for assisting an abused, entangled puppy.
This Video of a neglected puppy desperately seeking rescue from a mentally unstable and violently aggressive owner was taken recently at an RV park in Texas during our annual "Journey Across America" in support of Animal Welfare.
We've contacted Texas authorities, but the Sheriff’s Department informed us the…
Transform your Traditional Businesses Before Its Too Late
Mob Inspire, an app development company has disrupted many industries by providing innovative software solutions to traditional businesses. We understand the rapidly changing tech environment and therefore equipt ourselves with those skills and tech tools which enable us to deal with challenging situations efficiently.
Mob Inspire takes the leverage of the latest tech trends like Blockchain, IoT and Cloud to deliver high-end products to its clients. The popularity…
Late-Night Treats for Late-Night Peeps
WHAT: La Motta’s, the neighborhood favorite in Boston’s SoWa District, is rolling out the late-night red carpet for its hospitality industry folks and friends, with Chef de Cuisine Justin Winter’s creative twists on after-hours snacks. Available every Sunday - Thursday from 10:00PM to last call, La Motta’s is the neighborhood joint for a late-night bash with flavorful bites and brews.
Launching Sunday, February 26th, 2017, guests can expect flavorful options…
Late payment – the hidden challenge facing Europe's businesses
A recent Europe-wide business survey has revealed no improvement in the pressure on European businesses from customers’ late payments, with 55 per cent of businesses across Europe reporting late payments resulting in loss of income, 63 per cent claiming additional pressures on liquidity, and 50 per cent citing late payments as having a direct impact on company growth.
In the Republic of Ireland, 47 per cent of businesses surveyed claimed…